Rapafusyn Pharmaceuticals Closes Over-Subscribed $44 Million Series A Financing to Advance Its Non-Degrading Molecular Glue Drug Discovery Platform

▤ Summary

Rapafusyn Pharmaceuticals closed an oversubscribed Series A round and raised a total of $44 million. The company will use the capital to advance its RapaGlue platform, which discovers non-degrading molecular glues for hard-to-drug disease targets. The platform supports programs in oncology, immunology, renal disease, and pain, and Rapafusyn is moving its lead ENT1 inhibitor toward IND-enabling studies. The company also uses machine learning and AI in target selection and candidate optimization, and it continues to collaborate with a global pharmaceutical partner.

$ Funding

▦ Linked Companies